Brief: Xspray Pharma Re-Submits FDA Application For Dasynoc
26/02/2026 15:05
Feb 26 (Reuters) - XSpray Pharma AB (publ) XSPRAY.ST: RE-SUBMITS ITS FDA APPLICATION FOR DASYNOC WE MAINTAIN OUR PLAN TO LAUNCH TWO PRODUCTS, DASYNOC AND XS003 NILOTINIB DURING SECOND HALF OF 2026 NEW PDUFA-DATE IS EXPECTED TO BE SET FOR AUGUST 2026 AT LATEST Source text: ID:nMFNbK0qZZ Further company coverage: XSPRAY.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))